X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs IPCA LABS - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH IPCA LABS PANACEA BIOTECH/
IPCA LABS
 
P/E (TTM) x -22.3 36.4 - View Chart
P/BV x 3.1 3.5 90.5% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 PANACEA BIOTECH   IPCA LABS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
IPCA LABS
Mar-17
PANACEA BIOTECH/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs149643 23.1%   
Low Rs82503 16.4%   
Sales per share (Unadj.) Rs84.1254.4 33.1%  
Earnings per share (Unadj.) Rs-18.316.1 -113.9%  
Cash flow per share (Unadj.) Rs-6.729.8 -22.5%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7194.6 43.0%  
Shares outstanding (eoy) m61.25126.20 48.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.42.3 61.0%   
Avg P/E ratio x-6.335.7 -17.7%  
P/CF ratio (eoy) x-17.219.2 -89.6%  
Price / Book Value ratio x1.42.9 46.9%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m7,07472,300 9.8%   
No. of employees `0002.813.3 20.7%   
Total wages/salary Rs m1,4496,960 20.8%   
Avg. sales/employee Rs Th1,874.12,413.5 77.7%   
Avg. wages/employee Rs Th527.0523.2 100.7%   
Avg. net profit/employee Rs Th-407.7152.4 -267.5%   
INCOME DATA
Net Sales Rs m5,15432,106 16.1%  
Other income Rs m100226 44.2%   
Total revenues Rs m5,25432,332 16.2%   
Gross profit Rs m-7664,448 -17.2%  
Depreciation Rs m7111,730 41.1%   
Interest Rs m1,503241 624.2%   
Profit before tax Rs m-2,8812,703 -106.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17675 2.5%   
Profit after tax Rs m-1,1212,028 -55.3%  
Gross profit margin %-14.913.9 -107.3%  
Effective tax rate %-0.625.0 -2.3%   
Net profit margin %-21.86.3 -344.5%  
BALANCE SHEET DATA
Current assets Rs m3,81017,340 22.0%   
Current liabilities Rs m8,3659,559 87.5%   
Net working cap to sales %-88.424.2 -364.7%  
Current ratio x0.51.8 25.1%  
Inventory Days Days156100 155.2%  
Debtors Days Days6757 118.2%  
Net fixed assets Rs m14,48020,779 69.7%   
Share capital Rs m61252 24.3%   
"Free" reserves Rs m90324,499 3.7%   
Net worth Rs m5,12724,553 20.9%   
Long term debt Rs m5,8323,517 165.8%   
Total assets Rs m19,43339,595 49.1%  
Interest coverage x-0.912.2 -7.5%   
Debt to equity ratio x1.10.1 793.9%  
Sales to assets ratio x0.30.8 32.7%   
Return on assets %2.05.7 34.3%  
Return on equity %-21.98.3 -264.8%  
Return on capital %3.610.5 34.7%  
Exports to sales %24.548.6 50.4%   
Imports to sales %10.214.2 71.5%   
Exports (fob) Rs m1,26415,617 8.1%   
Imports (cif) Rs m5254,571 11.5%   
Fx inflow Rs m1,53915,617 9.9%   
Fx outflow Rs m9425,828 16.2%   
Net fx Rs m5979,790 6.1%   
CASH FLOW
From Operations Rs m5992,764 21.7%  
From Investments Rs m-438-1,432 30.6%  
From Financial Activity Rs m-303-1,591 19.0%  
Net Cashflow Rs m-141-259 54.6%  

Share Holding

Indian Promoters % 74.5 45.9 162.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.4 5.3%  
FIIs % 1.3 25.3 5.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.4 135.6%  
Shareholders   10,259 36,892 27.8%  
Pledged promoter(s) holding % 35.1 2.1 1,638.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jun 20, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - BIOCON LTD COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS